140 related articles for article (PubMed ID: 21079388)
1. Impact of gsp oncogene on the mRNA content for somatostatin and dopamine receptors in human somatotropinomas.
Taboada GF; Neto LV; Luque RM; Córdoba-Chacón J; de Oliveira Machado E; de Carvalho DP; Kineman RD; Gadelha MR
Neuroendocrinology; 2011; 93(1):40-7. PubMed ID: 21079388
[TBL] [Abstract][Full Text] [Related]
2. Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly.
Neto LV; Machado Ede O; Luque RM; Taboada GF; Marcondes JB; Chimelli LM; Quintella LP; Niemeyer P; de Carvalho DP; Kineman RD; Gadelha MR
J Clin Endocrinol Metab; 2009 Jun; 94(6):1931-7. PubMed ID: 19293270
[TBL] [Abstract][Full Text] [Related]
3. Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas.
Taboada GF; Luque RM; Bastos W; Guimarães RF; Marcondes JB; Chimelli LM; Fontes R; Mata PJ; Filho PN; Carvalho DP; Kineman RD; Gadelha MR
Eur J Endocrinol; 2007 Jan; 156(1):65-74. PubMed ID: 17218727
[TBL] [Abstract][Full Text] [Related]
4. Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR.
Taboada GF; Luque RM; Neto LV; Machado Ede O; Sbaffi BC; Domingues RC; Marcondes JB; Chimelli LM; Fontes R; Niemeyer P; de Carvalho DP; Kineman RD; Gadelha MR
Eur J Endocrinol; 2008 Mar; 158(3):295-303. PubMed ID: 18299461
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptors subtypes 2 and 5, dopamine receptor type 2 expression and gsp status as predictors of octreotide LAR responsiveness in acromegaly.
Vieira Neto L; Taboada GF; Gadelha MR
Arq Bras Endocrinol Metabol; 2008 Nov; 52(8):1288-95. PubMed ID: 19169483
[TBL] [Abstract][Full Text] [Related]
6. Impact of gsp oncogene on the expression of genes coding for Gsalpha, Pit-1, Gi2alpha, and somatostatin receptor 2 in human somatotroph adenomas: involvement in octreotide sensitivity.
Barlier A; Pellegrini-Bouiller I; Gunz G; Zamora AJ; Jaquet P; Enjalbert A
J Clin Endocrinol Metab; 1999 Aug; 84(8):2759-65. PubMed ID: 10443675
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment.
Horiguchi K; Yamada M; Umezawa R; Satoh T; Hashimoto K; Tosaka M; Yamada S; Mori M
Endocr J; 2007 Jun; 54(3):371-8. PubMed ID: 17420609
[TBL] [Abstract][Full Text] [Related]
8. ZAC1 and SSTR2 are downregulated in non-functioning pituitary adenomas but not in somatotropinomas.
Vieria Neto L; Wildemberg LE; Colli LM; Kasuki L; Marques NV; Moraes AB; Gasparetto EL; Takiya CM; Castro M; Gadelha MR
PLoS One; 2013; 8(10):e77406. PubMed ID: 24098585
[TBL] [Abstract][Full Text] [Related]
9. In vivo and in vitro response to octreotide LAR in a TSH-secreting adenoma: characterization of somatostatin receptor expression and role of subtype 5.
Gatto F; Barbieri F; Castelletti L; Arvigo M; Pattarozzi A; Annunziata F; Saveanu A; Minuto F; Castellan L; Zona G; Florio T; Ferone D
Pituitary; 2011 Jun; 14(2):141-7. PubMed ID: 21086053
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous srif activity and response to octreotide.
Park C; Yang I; Woo J; Kim S; Kim J; Kim Y; Sohn S; Kim E; Lee M; Park H; Jung J; Park S
Endocr J; 2004 Apr; 51(2):227-36. PubMed ID: 15118275
[TBL] [Abstract][Full Text] [Related]
11. Effect of gsp oncogene on somatostatin receptor subtype 1 and 2 mRNA levels in GHRH-responsive GH3 cells.
Kim E; Sohn S; Lee M; Park C; Jung J; Park S
Pituitary; 2005; 8(2):155-62. PubMed ID: 16379030
[TBL] [Abstract][Full Text] [Related]
12. Expression of somatostatin receptor (SSTR) subtypes in pituitary adenomas: quantitative analysis of SSTR2 mRNA by reverse transcription-polymerase chain reaction.
Murabe H; Shimatsu A; Ihara C; Mizuta H; Nakamura Y; Nagata I; Kikuchi H; Nakao K
J Neuroendocrinol; 1996 Aug; 8(8):605-10. PubMed ID: 8866248
[TBL] [Abstract][Full Text] [Related]
13. Does the response of GH-secreting pituitary adenomas to octreotide depend on the cellular localization of the somatostatin receptor subtypes SSTR2 and SSTR5?
Pisarek H; Pawlikowski M; Kunert-Radek J; Winczyk K
Endokrynol Pol; 2010; 61(2):178-81. PubMed ID: 20464704
[TBL] [Abstract][Full Text] [Related]
14. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
[TBL] [Abstract][Full Text] [Related]
15. Somatostatin receptor subtype gene expression in pituitary adenomas.
Miller GM; Alexander JM; Bikkal HA; Katznelson L; Zervas NT; Klibanski A
J Clin Endocrinol Metab; 1995 Apr; 80(4):1386-92. PubMed ID: 7714115
[TBL] [Abstract][Full Text] [Related]
16. Molecular and functional properties of densely and sparsely granulated GH-producing pituitary adenomas.
Mayr B; Buslei R; Theodoropoulou M; Stalla GK; Buchfelder M; Schöfl C
Eur J Endocrinol; 2013 Oct; 169(4):391-400. PubMed ID: 23847328
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors.
Shimon I; Yan X; Taylor JE; Weiss MH; Culler MD; Melmed S
J Clin Invest; 1997 Nov; 100(9):2386-92. PubMed ID: 9410919
[TBL] [Abstract][Full Text] [Related]
18. Expression of somatostatin receptor subtypes in human pituitary adenomas -- immunohistochemical studies.
Pisarek H; Pawlikowski M; Kunert-Radek J; Radek M
Endokrynol Pol; 2009; 60(4):240-51. PubMed ID: 19753537
[TBL] [Abstract][Full Text] [Related]
19. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs.
Matrone C; Pivonello R; Colao A; Cappabianca P; Cavallo LM; Del Basso De Caro ML; Taylor JE; Culler MD; Lombardi G; Di Renzo GF; Annunziato L
Neuroendocrinology; 2004 Mar; 79(3):142-8. PubMed ID: 15103227
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations.
Jaffrain-Rea ML; Rotondi S; Turchi A; Occhi G; Barlier A; Peverelli E; Rostomyan L; Defilles C; Angelini M; Oliva MA; Ceccato F; Maiorani O; Daly AF; Esposito V; Buttarelli F; Figarella-Branger D; Giangaspero F; Spada A; Scaroni C; Alesse E; Beckers A
Endocr Relat Cancer; 2013 Oct; 20(5):753-66. PubMed ID: 23940012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]